JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Béhé, M.
Right arrow Articles by Behr, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Béhé, M.
Right arrow Articles by Behr, T. M.
Journal of Nuclear Medicine Vol. 46 No. 6 1012-1015
© 2005 by Society of Nuclear Medicine


Basic Science Investigations

Use of Polyglutamic Acids to Reduce Uptake of Radiometal-Labeled Minigastrin in the Kidneys

Martin Béhé, PhD1, Gerald Kluge, MD2, Wolfgang Becker, MD2, Martin Gotthardt, MD1 and Thomas M. Behr, MD2

1 Department of Nuclear Medicine, Philipps-University of Marburg, Marburg, Germany
2 Department of Nuclear Medicine, Georg-August-University of Göttingen, Germany

Uptake of radiolabeled peptides in the kidneys may obscure abdominal tumors in radiopeptide scintigraphy. This problem is much more pronounced in peptide receptor radionuclide therapy (i.e., radiopeptide therapy), possibly leading to renal damage or even failure. Cationic peptide uptake in the kidneys can be reduced by the application of cationic amino acids, such as lysine or arginine. The aim of this study was to develop a suitable method to reduce anionic peptide uptake in the kidneys. 111In-Diethylenetriaminepentaacetic acid DGlu1-minigastrin (111In-DTPA-DGlu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) was chosen as a model compound with a sequence of 6 negatively charged glutamic acids in a chain and an additional aspartic acid. Methods: TT (human medullary carcinoma cells)-bearing nu/nu mice of the Institute of Cancer Research genotype received intraperitoneal injections of different chain lengths and weights of glutamic acids, aspartic acids, and derivatives of glutamic acids. Uptake in tumors and organs was determined and compared with the values for untreated control mice. Results: Accretion of 111In-DTPA-DGlu1-minigastrin in the kidneys could be reduced by up to 90%. The uptake values for all other organs and the tumors were not affected. These results were obtained with a chain of 5 or more glutamic acids, whereas uptake in kidneys was affected not at all or only slightly with poly-D-glutamic or polyaspartic acids and with Glux (x = 1–4). Conclusion: These studies indicated a specific blocking of uptake by Glu5 sequences in the kidneys. Application of polyglutamic acids is a new, successful method of reducing uptake of negatively charged peptides in the kidneys during radiopeptide therapy.

Key Words: minigastrin • peptide radiotherapy • kidney uptake • peptide receptor radionuclide therapy


Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 11a-12a. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
M. Gotthardt, J. van Eerd-Vismale, W. J.G. Oyen, M. de Jong, H. Zhang, E. Rolleman, H. R. Maecke, M. Behe, and O. Boerman
Indication for Different Mechanisms of Kidney Uptake of Radiolabeled Peptides
J. Nucl. Med., April 1, 2007; 48(4): 596 - 601.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S. J. Mather, A. J. McKenzie, J. K. Sosabowski, T. M. Morris, D. Ellison, and S. A. Watson
Selection of Radiolabeled Gastrin Analogs for Peptide Receptor-Targeted Radionuclide Therapy
J. Nucl. Med., April 1, 2007; 48(4): 615 - 622.
[Abstract] [Full Text] [PDF]


Home page
Veterinary PathologyHome page
K. A. B. Knostman, S. M. Jhiang, and C. C. Capen
Genetic Alterations in Thyroid Cancer: The Role of Mouse Models
Veterinary Pathology, January 1, 2007; 44(1): 1 - 14.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
M. Gotthardt, M. P Behe, J. Grass, A. Bauhofer, A. Rinke, M. L Schipper, M. Kalinowski, R. Arnold, W. J G Oyen, and T. M Behr
Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1203 - 1211.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. E.M. van Eerd, E. Vegt, J. F.M. Wetzels, F. G.M. Russel, R. Masereeuw, F. H.M. Corstens, W. J.G. Oyen, and O. C. Boerman
Gelatin-Based Plasma Expander Effectively Reduces Renal Uptake of 111In-Octreotide in Mice and Rats
J. Nucl. Med., March 1, 2006; 47(3): 528 - 533.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B. A. Nock, T. Maina, M. Behe, A. Nikolopoulou, M. Gotthardt, J. S. Schmitt, T. M. Behr, and H. R. Macke
CCK-2/Gastrin Receptor-Targeted Tumor Imaging with 99mTc-Labeled Minigastrin Analogs
J. Nucl. Med., October 1, 2005; 46(10): 1727 - 1736.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.